nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—ALB—Vandetanib—thyroid cancer	0.15	0.19	CbGbCtD
Enzalutamide—CYP2B6—Sorafenib—thyroid cancer	0.0921	0.117	CbGbCtD
Enzalutamide—CYP3A5—Sorafenib—thyroid cancer	0.0725	0.0922	CbGbCtD
Enzalutamide—CYP2C8—Sorafenib—thyroid cancer	0.0697	0.0886	CbGbCtD
Enzalutamide—CYP2C19—Sorafenib—thyroid cancer	0.0585	0.0744	CbGbCtD
Enzalutamide—CYP2B6—Doxorubicin—thyroid cancer	0.0559	0.071	CbGbCtD
Enzalutamide—CYP2C9—Sorafenib—thyroid cancer	0.0486	0.0618	CbGbCtD
Enzalutamide—ABCB1—Sorafenib—thyroid cancer	0.0472	0.06	CbGbCtD
Enzalutamide—CYP3A4—Vandetanib—thyroid cancer	0.0469	0.0596	CbGbCtD
Enzalutamide—CYP2D6—Sorafenib—thyroid cancer	0.0445	0.0565	CbGbCtD
Enzalutamide—ABCB1—Doxorubicin—thyroid cancer	0.0286	0.0364	CbGbCtD
Enzalutamide—CYP3A4—Sorafenib—thyroid cancer	0.0283	0.036	CbGbCtD
Enzalutamide—CYP2D6—Doxorubicin—thyroid cancer	0.027	0.0343	CbGbCtD
Enzalutamide—CYP3A4—Doxorubicin—thyroid cancer	0.0172	0.0218	CbGbCtD
Enzalutamide—Laryngitis—Vandetanib—thyroid cancer	0.00644	0.037	CcSEcCtD
Enzalutamide—Haematoma—Sorafenib—thyroid cancer	0.00499	0.0286	CcSEcCtD
Enzalutamide—Sepsis—Vandetanib—thyroid cancer	0.00403	0.0231	CcSEcCtD
Enzalutamide—Dry skin—Vandetanib—thyroid cancer	0.00309	0.0177	CcSEcCtD
Enzalutamide—Nasopharyngitis—Vandetanib—thyroid cancer	0.00302	0.0173	CcSEcCtD
Enzalutamide—Bronchitis—Vandetanib—thyroid cancer	0.0028	0.0161	CcSEcCtD
Enzalutamide—Neutropenia—Vandetanib—thyroid cancer	0.00273	0.0156	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00271	0.0155	CcSEcCtD
Enzalutamide—Pollakiuria—Vandetanib—thyroid cancer	0.00269	0.0154	CcSEcCtD
Enzalutamide—Pneumonia—Vandetanib—thyroid cancer	0.00261	0.015	CcSEcCtD
Enzalutamide—Infestation—Vandetanib—thyroid cancer	0.0026	0.0149	CcSEcCtD
Enzalutamide—Infestation NOS—Vandetanib—thyroid cancer	0.0026	0.0149	CcSEcCtD
Enzalutamide—Haematuria—Vandetanib—thyroid cancer	0.00248	0.0142	CcSEcCtD
Enzalutamide—Epistaxis—Vandetanib—thyroid cancer	0.00245	0.0141	CcSEcCtD
Enzalutamide—Sinusitis—Vandetanib—thyroid cancer	0.00244	0.014	CcSEcCtD
Enzalutamide—Urinary tract disorder—Vandetanib—thyroid cancer	0.0023	0.0132	CcSEcCtD
Enzalutamide—Urethral disorder—Vandetanib—thyroid cancer	0.00229	0.0131	CcSEcCtD
Enzalutamide—Angiopathy—Vandetanib—thyroid cancer	0.00212	0.0121	CcSEcCtD
Enzalutamide—Dry skin—Sorafenib—thyroid cancer	0.00209	0.012	CcSEcCtD
Enzalutamide—Mental disorder—Vandetanib—thyroid cancer	0.00204	0.0117	CcSEcCtD
Enzalutamide—Nasopharyngitis—Sorafenib—thyroid cancer	0.00203	0.0117	CcSEcCtD
Enzalutamide—Neutropenia—Sorafenib—thyroid cancer	0.00184	0.0105	CcSEcCtD
Enzalutamide—Pneumonia—Sorafenib—thyroid cancer	0.00176	0.0101	CcSEcCtD
Enzalutamide—Convulsion—Vandetanib—thyroid cancer	0.00176	0.0101	CcSEcCtD
Enzalutamide—Hypertension—Vandetanib—thyroid cancer	0.00175	0.0101	CcSEcCtD
Enzalutamide—Infestation NOS—Sorafenib—thyroid cancer	0.00175	0.0101	CcSEcCtD
Enzalutamide—Infestation—Sorafenib—thyroid cancer	0.00175	0.0101	CcSEcCtD
Enzalutamide—Arthralgia—Vandetanib—thyroid cancer	0.00173	0.00991	CcSEcCtD
Enzalutamide—Anxiety—Vandetanib—thyroid cancer	0.00172	0.00988	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00172	0.00985	CcSEcCtD
Enzalutamide—Epistaxis—Sorafenib—thyroid cancer	0.00165	0.00948	CcSEcCtD
Enzalutamide—Infection—Vandetanib—thyroid cancer	0.00165	0.00944	CcSEcCtD
Enzalutamide—Nervous system disorder—Vandetanib—thyroid cancer	0.00163	0.00932	CcSEcCtD
Enzalutamide—Thrombocytopenia—Vandetanib—thyroid cancer	0.00162	0.00931	CcSEcCtD
Enzalutamide—Skin disorder—Vandetanib—thyroid cancer	0.00161	0.00923	CcSEcCtD
Enzalutamide—Laryngitis—Epirubicin—thyroid cancer	0.00161	0.00921	CcSEcCtD
Enzalutamide—Urinary tract disorder—Sorafenib—thyroid cancer	0.00155	0.00891	CcSEcCtD
Enzalutamide—Connective tissue disorder—Sorafenib—thyroid cancer	0.00155	0.00887	CcSEcCtD
Enzalutamide—Urethral disorder—Sorafenib—thyroid cancer	0.00154	0.00885	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00151	0.00866	CcSEcCtD
Enzalutamide—Insomnia—Vandetanib—thyroid cancer	0.0015	0.0086	CcSEcCtD
Enzalutamide—Paraesthesia—Vandetanib—thyroid cancer	0.00149	0.00853	CcSEcCtD
Enzalutamide—Laryngitis—Doxorubicin—thyroid cancer	0.00149	0.00853	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00143	0.00821	CcSEcCtD
Enzalutamide—Fatigue—Vandetanib—thyroid cancer	0.00143	0.00819	CcSEcCtD
Enzalutamide—Angiopathy—Sorafenib—thyroid cancer	0.00143	0.00819	CcSEcCtD
Enzalutamide—Mental disorder—Sorafenib—thyroid cancer	0.00138	0.00791	CcSEcCtD
Enzalutamide—Leukopenia—Sorafenib—thyroid cancer	0.00123	0.00703	CcSEcCtD
Enzalutamide—Asthenia—Vandetanib—thyroid cancer	0.00119	0.00682	CcSEcCtD
Enzalutamide—Hypertension—Sorafenib—thyroid cancer	0.00118	0.00678	CcSEcCtD
Enzalutamide—Pruritus—Vandetanib—thyroid cancer	0.00117	0.00672	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00117	0.00672	CcSEcCtD
Enzalutamide—Arthralgia—Sorafenib—thyroid cancer	0.00117	0.00669	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00116	0.00664	CcSEcCtD
Enzalutamide—Diarrhoea—Vandetanib—thyroid cancer	0.00113	0.0065	CcSEcCtD
Enzalutamide—Infection—Sorafenib—thyroid cancer	0.00111	0.00637	CcSEcCtD
Enzalutamide—Nervous system disorder—Sorafenib—thyroid cancer	0.0011	0.00629	CcSEcCtD
Enzalutamide—Dizziness—Vandetanib—thyroid cancer	0.0011	0.00628	CcSEcCtD
Enzalutamide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00109	0.00628	CcSEcCtD
Enzalutamide—Skin disorder—Sorafenib—thyroid cancer	0.00109	0.00623	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00108	0.00622	CcSEcCtD
Enzalutamide—Headache—Vandetanib—thyroid cancer	0.00104	0.00595	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00102	0.00584	CcSEcCtD
Enzalutamide—Sepsis—Epirubicin—thyroid cancer	0.001	0.00576	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000965	0.00553	CcSEcCtD
Enzalutamide—Fatigue—Sorafenib—thyroid cancer	0.000964	0.00553	CcSEcCtD
Enzalutamide—Sepsis—Doxorubicin—thyroid cancer	0.00093	0.00533	CcSEcCtD
Enzalutamide—Hot flush—Epirubicin—thyroid cancer	0.000899	0.00515	CcSEcCtD
Enzalutamide—Menopausal symptoms—Epirubicin—thyroid cancer	0.000891	0.00511	CcSEcCtD
Enzalutamide—Hot flush—Doxorubicin—thyroid cancer	0.000832	0.00477	CcSEcCtD
Enzalutamide—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000824	0.00473	CcSEcCtD
Enzalutamide—Asthenia—Sorafenib—thyroid cancer	0.000802	0.0046	CcSEcCtD
Enzalutamide—Pruritus—Sorafenib—thyroid cancer	0.000791	0.00454	CcSEcCtD
Enzalutamide—Dry skin—Epirubicin—thyroid cancer	0.000771	0.00442	CcSEcCtD
Enzalutamide—Diarrhoea—Sorafenib—thyroid cancer	0.000765	0.00439	CcSEcCtD
Enzalutamide—Nasopharyngitis—Epirubicin—thyroid cancer	0.000752	0.00431	CcSEcCtD
Enzalutamide—Muscular weakness—Epirubicin—thyroid cancer	0.000741	0.00425	CcSEcCtD
Enzalutamide—Dizziness—Sorafenib—thyroid cancer	0.000739	0.00424	CcSEcCtD
Enzalutamide—Dry skin—Doxorubicin—thyroid cancer	0.000713	0.00409	CcSEcCtD
Enzalutamide—Headache—Sorafenib—thyroid cancer	0.0007	0.00402	CcSEcCtD
Enzalutamide—Bronchitis—Epirubicin—thyroid cancer	0.000699	0.00401	CcSEcCtD
Enzalutamide—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000696	0.00399	CcSEcCtD
Enzalutamide—Muscular weakness—Doxorubicin—thyroid cancer	0.000686	0.00393	CcSEcCtD
Enzalutamide—Neutropenia—Epirubicin—thyroid cancer	0.000679	0.0039	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000675	0.00387	CcSEcCtD
Enzalutamide—Pollakiuria—Epirubicin—thyroid cancer	0.000671	0.00385	CcSEcCtD
Enzalutamide—Pneumonia—Epirubicin—thyroid cancer	0.000652	0.00374	CcSEcCtD
Enzalutamide—Infestation—Epirubicin—thyroid cancer	0.000648	0.00371	CcSEcCtD
Enzalutamide—Infestation NOS—Epirubicin—thyroid cancer	0.000648	0.00371	CcSEcCtD
Enzalutamide—Bronchitis—Doxorubicin—thyroid cancer	0.000647	0.00371	CcSEcCtD
Enzalutamide—Neutropenia—Doxorubicin—thyroid cancer	0.000629	0.0036	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000625	0.00358	CcSEcCtD
Enzalutamide—Pollakiuria—Doxorubicin—thyroid cancer	0.000621	0.00356	CcSEcCtD
Enzalutamide—Haematuria—Epirubicin—thyroid cancer	0.000618	0.00354	CcSEcCtD
Enzalutamide—Epistaxis—Epirubicin—thyroid cancer	0.000611	0.0035	CcSEcCtD
Enzalutamide—Sinusitis—Epirubicin—thyroid cancer	0.000608	0.00349	CcSEcCtD
Enzalutamide—Pneumonia—Doxorubicin—thyroid cancer	0.000603	0.00346	CcSEcCtD
Enzalutamide—Infestation NOS—Doxorubicin—thyroid cancer	0.000599	0.00344	CcSEcCtD
Enzalutamide—Infestation—Doxorubicin—thyroid cancer	0.000599	0.00344	CcSEcCtD
Enzalutamide—Rhinitis—Epirubicin—thyroid cancer	0.000583	0.00334	CcSEcCtD
Enzalutamide—Hypoaesthesia—Epirubicin—thyroid cancer	0.000579	0.00332	CcSEcCtD
Enzalutamide—Pharyngitis—Epirubicin—thyroid cancer	0.000577	0.00331	CcSEcCtD
Enzalutamide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000574	0.00329	CcSEcCtD
Enzalutamide—Oedema peripheral—Epirubicin—thyroid cancer	0.000573	0.00329	CcSEcCtD
Enzalutamide—Haematuria—Doxorubicin—thyroid cancer	0.000572	0.00328	CcSEcCtD
Enzalutamide—Connective tissue disorder—Epirubicin—thyroid cancer	0.000571	0.00328	CcSEcCtD
Enzalutamide—Urethral disorder—Epirubicin—thyroid cancer	0.00057	0.00327	CcSEcCtD
Enzalutamide—Epistaxis—Doxorubicin—thyroid cancer	0.000565	0.00324	CcSEcCtD
Enzalutamide—Sinusitis—Doxorubicin—thyroid cancer	0.000562	0.00322	CcSEcCtD
Enzalutamide—Rhinitis—Doxorubicin—thyroid cancer	0.000539	0.00309	CcSEcCtD
Enzalutamide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000535	0.00307	CcSEcCtD
Enzalutamide—Pharyngitis—Doxorubicin—thyroid cancer	0.000534	0.00306	CcSEcCtD
Enzalutamide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000531	0.00305	CcSEcCtD
Enzalutamide—Oedema peripheral—Doxorubicin—thyroid cancer	0.00053	0.00304	CcSEcCtD
Enzalutamide—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000529	0.00303	CcSEcCtD
Enzalutamide—Angiopathy—Epirubicin—thyroid cancer	0.000528	0.00303	CcSEcCtD
Enzalutamide—Urethral disorder—Doxorubicin—thyroid cancer	0.000527	0.00302	CcSEcCtD
Enzalutamide—Mental disorder—Epirubicin—thyroid cancer	0.00051	0.00292	CcSEcCtD
Enzalutamide—Back pain—Epirubicin—thyroid cancer	0.00049	0.00281	CcSEcCtD
Enzalutamide—Angiopathy—Doxorubicin—thyroid cancer	0.000488	0.0028	CcSEcCtD
Enzalutamide—Mental disorder—Doxorubicin—thyroid cancer	0.000471	0.0027	CcSEcCtD
Enzalutamide—Vertigo—Epirubicin—thyroid cancer	0.000455	0.00261	CcSEcCtD
Enzalutamide—Leukopenia—Epirubicin—thyroid cancer	0.000453	0.0026	CcSEcCtD
Enzalutamide—Back pain—Doxorubicin—thyroid cancer	0.000453	0.0026	CcSEcCtD
Enzalutamide—Convulsion—Epirubicin—thyroid cancer	0.000439	0.00252	CcSEcCtD
Enzalutamide—Hypertension—Epirubicin—thyroid cancer	0.000437	0.00251	CcSEcCtD
Enzalutamide—Arthralgia—Epirubicin—thyroid cancer	0.000431	0.00247	CcSEcCtD
Enzalutamide—Anxiety—Epirubicin—thyroid cancer	0.00043	0.00246	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000428	0.00245	CcSEcCtD
Enzalutamide—Vertigo—Doxorubicin—thyroid cancer	0.000421	0.00241	CcSEcCtD
Enzalutamide—Leukopenia—Doxorubicin—thyroid cancer	0.000419	0.0024	CcSEcCtD
Enzalutamide—CYP2B6—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000418	0.0107	CbGpPWpGaD
Enzalutamide—AR—Nuclear Receptors—PPARG—thyroid cancer	0.000417	0.0107	CbGpPWpGaD
Enzalutamide—AR—Notch-mediated HES/HEY network—HIF1A—thyroid cancer	0.000413	0.0106	CbGpPWpGaD
Enzalutamide—Infection—Epirubicin—thyroid cancer	0.00041	0.00235	CcSEcCtD
Enzalutamide—CYP3A5—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000409	0.0105	CbGpPWpGaD
Enzalutamide—Convulsion—Doxorubicin—thyroid cancer	0.000406	0.00233	CcSEcCtD
Enzalutamide—Nervous system disorder—Epirubicin—thyroid cancer	0.000405	0.00232	CcSEcCtD
Enzalutamide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000405	0.00232	CcSEcCtD
Enzalutamide—Hypertension—Doxorubicin—thyroid cancer	0.000404	0.00232	CcSEcCtD
Enzalutamide—Skin disorder—Epirubicin—thyroid cancer	0.000401	0.0023	CcSEcCtD
Enzalutamide—Arthralgia—Doxorubicin—thyroid cancer	0.000399	0.00229	CcSEcCtD
Enzalutamide—Anxiety—Doxorubicin—thyroid cancer	0.000397	0.00228	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000396	0.00227	CcSEcCtD
Enzalutamide—Infection—Doxorubicin—thyroid cancer	0.00038	0.00218	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000376	0.00216	CcSEcCtD
Enzalutamide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000375	0.00215	CcSEcCtD
Enzalutamide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000374	0.00215	CcSEcCtD
Enzalutamide—Insomnia—Epirubicin—thyroid cancer	0.000374	0.00214	CcSEcCtD
Enzalutamide—Skin disorder—Doxorubicin—thyroid cancer	0.000371	0.00213	CcSEcCtD
Enzalutamide—Paraesthesia—Epirubicin—thyroid cancer	0.000371	0.00213	CcSEcCtD
Enzalutamide—CYP2B6—Metapathway biotransformation—CHST14—thyroid cancer	0.000369	0.00946	CbGpPWpGaD
Enzalutamide—CYP3A5—Metapathway biotransformation—CHST14—thyroid cancer	0.000361	0.00925	CbGpPWpGaD
Enzalutamide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000357	0.00205	CcSEcCtD
Enzalutamide—Fatigue—Epirubicin—thyroid cancer	0.000356	0.00204	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000348	0.002	CcSEcCtD
Enzalutamide—AR—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.000348	0.00892	CbGpPWpGaD
Enzalutamide—Insomnia—Doxorubicin—thyroid cancer	0.000346	0.00198	CcSEcCtD
Enzalutamide—Paraesthesia—Doxorubicin—thyroid cancer	0.000343	0.00197	CcSEcCtD
Enzalutamide—AR—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000334	0.00855	CbGpPWpGaD
Enzalutamide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00033	0.00189	CcSEcCtD
Enzalutamide—Fatigue—Doxorubicin—thyroid cancer	0.00033	0.00189	CcSEcCtD
Enzalutamide—AR—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000329	0.00844	CbGpPWpGaD
Enzalutamide—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000321	0.00822	CbGpPWpGaD
Enzalutamide—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000316	0.00811	CbGpPWpGaD
Enzalutamide—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.000313	0.00801	CbGpPWpGaD
Enzalutamide—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000309	0.00791	CbGpPWpGaD
Enzalutamide—Asthenia—Epirubicin—thyroid cancer	0.000296	0.0017	CcSEcCtD
Enzalutamide—AR—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000293	0.00752	CbGpPWpGaD
Enzalutamide—Pruritus—Epirubicin—thyroid cancer	0.000292	0.00168	CcSEcCtD
Enzalutamide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000289	0.0074	CbGpPWpGaD
Enzalutamide—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000288	0.00739	CbGpPWpGaD
Enzalutamide—Diarrhoea—Epirubicin—thyroid cancer	0.000283	0.00162	CcSEcCtD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—thyroid cancer	0.000283	0.00724	CbGpPWpGaD
Enzalutamide—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	0.000279	0.00715	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000275	0.00705	CbGpPWpGaD
Enzalutamide—Asthenia—Doxorubicin—thyroid cancer	0.000274	0.00157	CcSEcCtD
Enzalutamide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000274	0.00702	CbGpPWpGaD
Enzalutamide—Dizziness—Epirubicin—thyroid cancer	0.000273	0.00157	CcSEcCtD
Enzalutamide—Pruritus—Doxorubicin—thyroid cancer	0.00027	0.00155	CcSEcCtD
Enzalutamide—AR—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000264	0.00676	CbGpPWpGaD
Enzalutamide—Diarrhoea—Doxorubicin—thyroid cancer	0.000262	0.0015	CcSEcCtD
Enzalutamide—Headache—Epirubicin—thyroid cancer	0.000259	0.00148	CcSEcCtD
Enzalutamide—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.000257	0.00658	CbGpPWpGaD
Enzalutamide—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000254	0.00652	CbGpPWpGaD
Enzalutamide—CYP2B6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000253	0.00649	CbGpPWpGaD
Enzalutamide—Dizziness—Doxorubicin—thyroid cancer	0.000253	0.00145	CcSEcCtD
Enzalutamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000252	0.00645	CbGpPWpGaD
Enzalutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000247	0.00634	CbGpPWpGaD
Enzalutamide—Headache—Doxorubicin—thyroid cancer	0.000239	0.00137	CcSEcCtD
Enzalutamide—AR—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.00022	0.00563	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000216	0.00553	CbGpPWpGaD
Enzalutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000214	0.00549	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—THRB—thyroid cancer	0.000212	0.00544	CbGpPWpGaD
Enzalutamide—CYP2B6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000205	0.00526	CbGpPWpGaD
Enzalutamide—AR—Coregulation of Androgen receptor activity—CCND1—thyroid cancer	0.000203	0.0052	CbGpPWpGaD
Enzalutamide—CYP3A5—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000201	0.00514	CbGpPWpGaD
Enzalutamide—AR—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.000194	0.00497	CbGpPWpGaD
Enzalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000191	0.0049	CbGpPWpGaD
Enzalutamide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00019	0.00488	CbGpPWpGaD
Enzalutamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000186	0.00476	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000181	0.00465	CbGpPWpGaD
Enzalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000176	0.00451	CbGpPWpGaD
Enzalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000174	0.00447	CbGpPWpGaD
Enzalutamide—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000174	0.00445	CbGpPWpGaD
Enzalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000173	0.00445	CbGpPWpGaD
Enzalutamide—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000168	0.0043	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—thyroid cancer	0.000163	0.00419	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000158	0.00406	CbGpPWpGaD
Enzalutamide—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000155	0.00398	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—CCND1—thyroid cancer	0.00015	0.00384	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—PTEN—thyroid cancer	0.000145	0.00371	CbGpPWpGaD
Enzalutamide—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000143	0.00366	CbGpPWpGaD
Enzalutamide—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000141	0.00362	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—TRIM33—thyroid cancer	0.000141	0.00362	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—MEN1—thyroid cancer	0.000135	0.00345	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000135	0.00345	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000134	0.00344	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000128	0.00329	CbGpPWpGaD
Enzalutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000123	0.00316	CbGpPWpGaD
Enzalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000115	0.00295	CbGpPWpGaD
Enzalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000114	0.00293	CbGpPWpGaD
Enzalutamide—AR—Coregulation of Androgen receptor activity—AKT1—thyroid cancer	0.000113	0.00289	CbGpPWpGaD
Enzalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00011	0.00282	CbGpPWpGaD
Enzalutamide—CYP2B6—Biological oxidations—RXRA—thyroid cancer	0.000109	0.00279	CbGpPWpGaD
Enzalutamide—CYP3A5—Biological oxidations—RXRA—thyroid cancer	0.000107	0.00273	CbGpPWpGaD
Enzalutamide—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000105	0.00269	CbGpPWpGaD
Enzalutamide—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000105	0.00269	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—THRB—thyroid cancer	0.000102	0.00262	CbGpPWpGaD
Enzalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.0001	0.00257	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	9.82e-05	0.00252	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.81e-05	0.00251	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.75e-05	0.0025	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	9.48e-05	0.00243	CbGpPWpGaD
Enzalutamide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	9.32e-05	0.00239	CbGpPWpGaD
Enzalutamide—CYP2C8—Biological oxidations—RXRA—thyroid cancer	9.23e-05	0.00237	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—RXRA—thyroid cancer	9.01e-05	0.00231	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	9.01e-05	0.00231	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	8.99e-05	0.00231	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.76e-05	0.00224	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—AKT1—thyroid cancer	8.34e-05	0.00214	CbGpPWpGaD
Enzalutamide—CYP2C19—Biological oxidations—RXRA—thyroid cancer	8.24e-05	0.00211	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	8.14e-05	0.00209	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—MINPP1—thyroid cancer	8.01e-05	0.00205	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	7.98e-05	0.00205	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.86e-05	0.00201	CbGpPWpGaD
Enzalutamide—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	7.85e-05	0.00201	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—MINPP1—thyroid cancer	7.83e-05	0.00201	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	7.79e-05	0.002	CbGpPWpGaD
Enzalutamide—CYP2D6—Biological oxidations—RXRA—thyroid cancer	7.58e-05	0.00194	CbGpPWpGaD
Enzalutamide—CYP2C9—Biological oxidations—RXRA—thyroid cancer	7.51e-05	0.00193	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	7.39e-05	0.0019	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	7.28e-05	0.00187	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—TPR—thyroid cancer	6.9e-05	0.00177	CbGpPWpGaD
Enzalutamide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	6.82e-05	0.00175	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—NDUFA13—thyroid cancer	6.81e-05	0.00175	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—MINPP1—thyroid cancer	6.78e-05	0.00174	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—MINPP1—thyroid cancer	6.74e-05	0.00173	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—NDUFA13—thyroid cancer	6.65e-05	0.00171	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MEN1—thyroid cancer	6.48e-05	0.00166	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	6.47e-05	0.00166	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CHST14—thyroid cancer	6.4e-05	0.00164	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CHST14—thyroid cancer	6.26e-05	0.0016	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PRKAR1A—thyroid cancer	6.05e-05	0.00155	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—MINPP1—thyroid cancer	6.05e-05	0.00155	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.03e-05	0.00155	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—MINPP1—thyroid cancer	5.91e-05	0.00151	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—TP53—thyroid cancer	5.84e-05	0.0015	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—NDUFA13—thyroid cancer	5.76e-05	0.00148	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—NDUFA13—thyroid cancer	5.73e-05	0.00147	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—PPARG—thyroid cancer	5.69e-05	0.00146	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—MINPP1—thyroid cancer	5.57e-05	0.00143	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—MINPP1—thyroid cancer	5.52e-05	0.00141	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	5.46e-05	0.0014	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CHST14—thyroid cancer	5.42e-05	0.00139	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CHST14—thyroid cancer	5.39e-05	0.00138	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.36e-05	0.00137	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	5.33e-05	0.00137	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	5.33e-05	0.00137	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.24e-05	0.00134	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—HPGD—thyroid cancer	5.16e-05	0.00132	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—NDUFA13—thyroid cancer	5.14e-05	0.00132	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—HPGD—thyroid cancer	5.04e-05	0.00129	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—NDUFA13—thyroid cancer	5.02e-05	0.00129	CbGpPWpGaD
Enzalutamide—CYP3A4—Biological oxidations—RXRA—thyroid cancer	4.95e-05	0.00127	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CHST14—thyroid cancer	4.84e-05	0.00124	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—NDUFA13—thyroid cancer	4.73e-05	0.00121	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CHST14—thyroid cancer	4.72e-05	0.00121	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.69e-05	0.0012	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.67e-05	0.0012	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	4.67e-05	0.0012	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	4.59e-05	0.00118	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.53e-05	0.00116	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CHST14—thyroid cancer	4.45e-05	0.00114	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CHST14—thyroid cancer	4.41e-05	0.00113	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—HPGD—thyroid cancer	4.37e-05	0.00112	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—HPGD—thyroid cancer	4.34e-05	0.00111	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—RXRA—thyroid cancer	4.34e-05	0.00111	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	4.32e-05	0.00111	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IFNA2—thyroid cancer	4.01e-05	0.00103	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.99e-05	0.00102	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—HPGD—thyroid cancer	3.9e-05	0.001	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—HPGD—thyroid cancer	3.81e-05	0.000976	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.67e-05	0.000941	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.64e-05	0.000933	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—HPGD—thyroid cancer	3.59e-05	0.000919	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—HPGD—thyroid cancer	3.56e-05	0.000911	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.54e-05	0.000908	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.52e-05	0.000903	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.49e-05	0.000896	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.35e-05	0.000859	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.32e-05	0.000851	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.2e-05	0.000821	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.16e-05	0.000811	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.09e-05	0.000793	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—TPR—thyroid cancer	2.96e-05	0.00076	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.94e-05	0.000753	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	2.92e-05	0.000747	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CHST14—thyroid cancer	2.91e-05	0.000746	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—TPR—thyroid cancer	2.9e-05	0.000743	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.88e-05	0.000739	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	2.85e-05	0.000731	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PPARG—thyroid cancer	2.74e-05	0.000702	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—TPR—thyroid cancer	2.51e-05	0.000643	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—TPR—thyroid cancer	2.49e-05	0.00064	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.47e-05	0.000633	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.46e-05	0.00063	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PRKAR1A—thyroid cancer	2.45e-05	0.000629	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—HPGD—thyroid cancer	2.34e-05	0.000601	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—TPR—thyroid cancer	2.24e-05	0.000574	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.24e-05	0.000574	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.22e-05	0.00057	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—SLC5A5—thyroid cancer	2.22e-05	0.000569	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	2.2e-05	0.000565	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—TPR—thyroid cancer	2.19e-05	0.00056	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.19e-05	0.00056	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—SLC5A5—thyroid cancer	2.17e-05	0.000556	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.15e-05	0.000551	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—TPR—thyroid cancer	2.06e-05	0.000528	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—TPR—thyroid cancer	2.04e-05	0.000523	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	2.03e-05	0.00052	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.01e-05	0.000515	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2e-05	0.000512	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.88e-05	0.000482	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.87e-05	0.00048	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—SLC5A5—thyroid cancer	1.87e-05	0.000479	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—RXRA—thyroid cancer	1.86e-05	0.000478	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.85e-05	0.000473	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—RXRA—thyroid cancer	1.82e-05	0.000467	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.82e-05	0.000467	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.76e-05	0.000451	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.75e-05	0.000449	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.68e-05	0.00043	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.64e-05	0.000419	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—RXRA—thyroid cancer	1.58e-05	0.000405	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.57e-05	0.000403	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—RXRA—thyroid cancer	1.57e-05	0.000402	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.54e-05	0.000395	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.53e-05	0.000393	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.53e-05	0.000392	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.53e-05	0.000391	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—NRAS—thyroid cancer	1.5e-05	0.000383	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.43e-05	0.000367	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—RXRA—thyroid cancer	1.41e-05	0.000361	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—RXRA—thyroid cancer	1.37e-05	0.000352	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.37e-05	0.000351	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—TPR—thyroid cancer	1.35e-05	0.000345	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.32e-05	0.00034	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—RXRA—thyroid cancer	1.3e-05	0.000332	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—KRAS—thyroid cancer	1.29e-05	0.00033	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—RXRA—thyroid cancer	1.28e-05	0.000329	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.25e-05	0.00032	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PPARG—thyroid cancer	1.18e-05	0.000302	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PPARG—thyroid cancer	1.15e-05	0.000295	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TP53—thyroid cancer	1.14e-05	0.000293	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—HRAS—thyroid cancer	1.09e-05	0.00028	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—AKT1—thyroid cancer	1.08e-05	0.000278	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.01e-05	0.000258	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PPARG—thyroid cancer	9.96e-06	0.000255	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PPARG—thyroid cancer	9.91e-06	0.000254	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—AKT1—thyroid cancer	9.66e-06	0.000248	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTGS2—thyroid cancer	9.26e-06	0.000237	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTGS2—thyroid cancer	9.05e-06	0.000232	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PPARG—thyroid cancer	8.89e-06	0.000228	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PPARG—thyroid cancer	8.68e-06	0.000223	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—RXRA—thyroid cancer	8.47e-06	0.000217	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PPARG—thyroid cancer	8.18e-06	0.00021	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PPARG—thyroid cancer	8.11e-06	0.000208	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTEN—thyroid cancer	8.07e-06	0.000207	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTEN—thyroid cancer	7.89e-06	0.000202	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTGS2—thyroid cancer	7.84e-06	0.000201	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTGS2—thyroid cancer	7.79e-06	0.0002	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTGS2—thyroid cancer	7e-06	0.000179	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTEN—thyroid cancer	6.84e-06	0.000175	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTGS2—thyroid cancer	6.83e-06	0.000175	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTEN—thyroid cancer	6.8e-06	0.000174	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTGS2—thyroid cancer	6.43e-06	0.000165	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTGS2—thyroid cancer	6.38e-06	0.000164	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTEN—thyroid cancer	6.1e-06	0.000156	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTEN—thyroid cancer	5.95e-06	0.000153	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTEN—thyroid cancer	5.61e-06	0.000144	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTEN—thyroid cancer	5.56e-06	0.000143	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PPARG—thyroid cancer	5.35e-06	0.000137	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—AKT1—thyroid cancer	4.65e-06	0.000119	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—AKT1—thyroid cancer	4.55e-06	0.000117	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.21e-06	0.000108	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—AKT1—thyroid cancer	3.94e-06	0.000101	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—AKT1—thyroid cancer	3.92e-06	0.0001	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTEN—thyroid cancer	3.67e-06	9.41e-05	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—AKT1—thyroid cancer	3.52e-06	9.01e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—AKT1—thyroid cancer	3.43e-06	8.8e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—AKT1—thyroid cancer	3.23e-06	8.29e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—AKT1—thyroid cancer	3.21e-06	8.22e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—AKT1—thyroid cancer	2.11e-06	5.42e-05	CbGpPWpGaD
